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Purpose: Diuretics are the primary treatment for the management of chronic heart failure 
(HF) symptoms and for the improvement of acute HF symptoms. The rate of delivery to the 
site of action has been suggested to affect diuretic pharmacodynamics. The main objective of 
this clinical trial was to explore whether a prolonged release tablet formulation of torasemide 
(torasemide-PR) was more natriuretically efficient in patients with chronic HF compared to 
immediate-release furosemide (furosemide-IR) after a single-dose administration. Moreover, 
the pharmacokinetics of torasemide-PR, furosemide-IR, and torasemide-IR were assessed in 
chronic HF patients as well as urine pharmacodynamics.
Methods: Randomized, open-label, blinded-endpoint, crossover, and single-dose Phase I clini-
cal trial with three experimental periods. Torasemide-PR and furosemide-IR were administered 
as a single dose in a crossover fashion for the first two periods, and torasemide-IR 10 mg was 
administered for the third period. Blood and urine samples were collected at fixed timepoints. 
The primary endpoint was the natriuretic efficiency after administration of torasemide-PR and 
furosemide-IR, defined as the ratio between the average drug-induced natriuresis and the aver-
age drug recovered in urine over 24 hours.
Results: Ten patients were included and nine completed the study. Here, we present the results 
from nine patients. Torasemide-PR was more natriuretically efficient than furosemide-IR 
(0.096±0.03 mmol/μg vs 0.015±0.0007 mmol/μg; P,0.0001). Mictional urgency was lower 
and more delayed with torasemide-PR than with furosemide-IR.
Conclusion: In a study with a limited sample size, our results suggest that 10 mg of 
torasemide-PR is more natriuretically efficient than 40 mg of furosemide-IR after single-dose 
administration in patients with chronic HF over a 24-hour collection period. Further studies are 
necessary to evaluate potential pharmacodynamic differences between torasemide formulations 
and to assess its impact on clinical therapeutics.
Keywords: torasemide, furosemide, controlled-release preparation, efficiency, heart failure, 
pharmacodynamics
Introduction
Heart failure (HF) is associated with fluid retention and is one of the leading causes 
of morbidity and mortality in the world.1,2 Among the wide range of pharmacological 
treatments available, diuretics continue to play an essential role in the management 
of fluid overload symptoms.2,3 Torasemide is a high-ceiling loop diuretic that inhibits 
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the Na+–K+–2Cl− reabsorptive pump in the medullary portion 
of the thick ascending limb of the loop of Henle, resulting in 
pronounced saluresis and diuresis.2,4 It is rapidly absorbed 
following oral administration, achieving the peak plasma 
concentration (C
max
) within the first hour. Metabolism of 
torasemide involves hepatic biotransformation, with up 
to 25% of an intravenous dose being excreted unchanged 
in the urine. Linear pharmacokinetics of torasemide have 
been observed after intravenous and oral administration of 
20–200 mg and oral doses of 50–200 mg to patients with renal 
failure and congestive heart failure (CHF), respectively.4 
On a mole per mole basis, torasemide is more than twice as 
active compared to furosemide.5
In CHF patients, the bioavailability of torasemide is the 
same as that observed in healthy volunteers with values 
approximating 90%.6,7 Vargo et al6 studied the pharmacoki-
netics of torasemide and furosemide in patients with CHF 
(classes II and III) and compared them to the pharmacokinetic 
profiles in healthy subjects.8 C
max
 and t
max
 of torasemide in 
CHF patients were compared to that reported in healthy 
subjects, thus indicating that CHF did not affect the rate 
of absorption of torasemide after oral administration. By 
contrast, delayed absorption of furosemide was observed. 
Compared to healthy subjects, patients with CHF showed no 
pharmacokinetic changes for torasemide, with the exception 
of decreased chloride and increased V
ss
. Based on urinary 
excretion data, the pharmacokinetics of torasemide in this 
patient population are linear up to doses of at least 200 mg.6,9 
As for pharmacodynamic effects, a rapid onset of action for 
torasemide with a significant increase in diuresis has been 
observed in healthy volunteers.10 In patients with chronic 
CHF, 10–20 mg of torasemide appears to produce greater 
saluresis and diuresis than 40 mg of furosemide; however, 
urinary potassium excretion does not follow the dose-
related increase observed for sodium and chloride excretion 
after single doses of torasemide of up to 20 mg.4 Some 
clinical studies propose that torasemide could have a longer 
duration of action and improved tolerability compared to 
furosemide.3,11 Furthermore, a greater proportion of patients 
who received torasemide showed improved functional class 
(45.8 vs 37.2, P,0.00017) than compared with those who 
received furosemide.11 Additionally, torasemide could be a 
cost-saving option compared to furosemide.12
Conventionally, immediate-release (IR) formulations 
are quickly released into the bloodstream and, after rapid 
excretion of the drug, plasma concentrations fall sharply to 
subtherapeutic levels. This can lead to a decrease in drug 
efficacy depending on the clinical indication. This effect 
can be minimized by the administration of prolonged-
release (PR) formulations. A PR formulation of torasemide 
(torasemide-PR) has been found to elicit a more physiological 
response in healthy subjects, resulting in a urinary excretion 
rate associated with a higher natriuretic efficiency and a more 
constant diuresis than the IR formulation.13
The main objective of this clinical trial was to explore 
whether torasemide given as PR tablet (torasemide-PR) was 
more natriuretically efficient in patients with chronic HF 
compared to IR furosemide (furosemide-IR) after a single-
dose administration. As secondary objectives, the pharma-
cokinetic and pharmacodynamic profiles of torasemide-PR, 
torasemide-IR, and furosemide-IR were explored.
Methods
subjects
Inclusion and exclusion criteria are summarized in Table 1.
study design and treatments
The study was a randomized, open-label, blinded-endpoint, 
crossover, and single-dose Phase I clinical trial with three 
experimental periods (EU Clinical Trials Register: registra-
tion number 2011-000972-32 [www.clinicaltrialsregister.eu]; 
Clinical Trials registration number NCT01549158 [www.
clinicaltrials.gov]). It was conducted in the Drug Research 
Center (CIM, IIB Sant Pau), and patients were recruited 
from the Cardiology Department of the Hospital de la Santa 
Creu i Sant Pau as well as from three primary care centers 
(Barcelona, Spain).
Prior to initiation, the study protocol and the informed 
consent that was signed by the eligible patients, was approved 
by an independent ethics committee (Comité Ético de Inves-
tigación Clínica del Hospital de la Santa Creu i Sant Pau 
in Barcelona, Spain) and the national competent authority 
(AEMPS, Spain).
The study included a screening evaluation after a 10-hour 
fasting period prior to the initiation of any study procedures 
and an end-of-study evaluation for all patients (physical 
examination including vital signs, electrocardiogram [ECG], 
and laboratory analyses).
The experimental phase consisted of three separate periods 
with a 7-day washout period (Figure 1). The included patients 
were randomized to receive torasemide-PR (Sutril Neo® 
10 mg tablets; Ferrer Internacional S.A., Barcelona, Spain) or 
furosemide-IR (Seguril® 40 mg, tablets, Sanofi-Aventis SA, 
Barcelona, Spain) for the first period, and they subsequently 
received the alternate drug for the second period. All the 
participants received torasemide-IR (Sutril® 10 mg tablets; 
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Figure 1 study schedule.
Notes: The study consisted of three periods separated with a 7-day washout. The first and second period were crossover between torasemide PR and furosemide-IR 
whereas in the third period the patients taken Torasemide-ir.
Abbreviations: h, hours; Pr, prolonged release; ir, immediate release.
Ferrer Internacional SA, Barcelona, Spain) in the third period 
to minimize the impact of patient withdrawals during the study 
on the main study objective. Doses for the study were chosen 
according to clinical practice and authorized indications.
Participants were required to follow a controlled diet 
(30 mEq Na/day, 60 mEq K/day, 1–1.5 g/kg protein/day) 
during the 5 days prior to dosing in each of the three peri-
ods, in order to ensure an appropriate sodium balance. This 
sodium balance was defined as the maintenance of a stable 
weight and an absence of sodium excretion fluctuations 
in the urine over 24 hours. In the morning of the fifth day 
prior to dosing (D-5), patients were given a bottle to collect 
urine for 24 hours, until the morning of the fourth day prior 
to dosing (D-4). Sodium (mEq) was analyzed in urine, and 
patients were weighed 24 hours before dosing; day-1 (D1) of 
each study period. In the morning of the study day 1 (D1) of 
each study period, a single dose of the drug was given with 
180 mL of water in fasting conditions. Patients rested in a 
supine position for the first 8 hours after the administration 
to avoid the attenuation of the natriuretic response.14 Vital 
signs were measured using a DINAMAP® sphygmomanom-
eter (Critikon, Inc., Tampa, FL, USA). ECG were recorded 
using a Pagewrite 300pi ECG recorder (Hewlett Packard, 
Palo Alto, CA, USA). Hematology, biochemistry, and urine 
parameters were evaluated before and after each period. No 
medications were permitted during the study, except for those 
allowed in the selection criteria.
study endpoints
The primary endpoint was the natriuretic efficiency 
after the administration of torasemide-PR and furosemide-IR. 
The efficiency concept is an alternative way to describe 
the pharmacological effect, in terms of effect per unit drug 
concentration, instead of simple effect. However, for loop 
diuretics, urinary drug concentrations more accurately 
reflect the effect compared to plasma concentrations.15 In 
the present study, the total efficiency for the studied diuretics 
was defined as the ratio between the average drug-induced 
natriuresis (Ae
Na
) and the average drug recovered in urine 
(Ae
drug
) over 24 hours. Secondary endpoints included other 
pharmacokinetic/pharmacodynamic (PK/PD) parameters 
of the study drugs, as well as urinary urgency assessed by a 
visual analog scale (VAS).
PK/PD determinations
For PK parameter evaluations, blood samples were taken for 
the determination of plasma concentrations of torasemide and 
furosemide. Urine samples were also taken to assess drug 
and ion excretion. The following PD parameters were also 
evaluated: diuretic effect of each study medication, measured 
as the volume of urine collected during different intervals 
(drug-induced diuresis) and at 24 hours; the diuresis rate in 
those intervals; and sodium, potassium, and chloride excre-
tion rate (ER
Na
, ER
K
, ER
Cl
, respectively).
Urine samples were collected 12 hours before each 
study drug administration and 0–0.5 hour, 0.5–1 hour, 
1–1.5 hours, 1.5–2 hours, 2–3 hours, 3–4 hours, 4–6 hours, 
6–8 hours, 8–12 hours, 12–24 hours postdose intervals. Blood 
samples were collected at baseline (prior to drug adminis-
tration), and +0.25 hour, +0.5 hour, +0.75 hour, +1 hour, 
+1.25 hours, +1.5 hours, +1.75 hours, 2 hours, +2.5 hours, 
+3.5 hours, +4.5 hours, +5.5 hours, +7 hours, +10 hours, 
+18 hours, +24 hours, after study drug administration.
Blood samples (5.0 mL per sample, 17 samples per 
patient per period) were collected into lithium-heparinized 
tubes for PK analysis. Samples were centrifuged no later than 
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30 minutes after collection for 10 minutes at 3,000 rpm at 
4°C, and the resulting plasma samples were separated into 
two aliquots of 0.7 mL each that were stored at −80°C.
C
max
 and time to reach peak (t
max
) were obtained 
directly from the raw data. The terminal plasma elimina-
tion half-life (t
1/2
) was calculated as t
1/2
=0.639/k
e
, where 
k
e
 represents the first-order elimination rate constant 
associated with the terminal (log linear) portion of the 
curve, estimated via linear regression of time versus log 
concentration. The area under the plasma concentration–
time curve (AUC) from 0 to ∞ (AUC
0–∞) was calculated as 
AUC
0–∞ = AUC0–tx + Ctx/ke, where tx is the time of the last 
torasemide or furosemide concentration (Ct
x
), exceeding 
the limit of quantification. Partial AUC values with 0 hours 
and 24 hours as time limits (AUC
0–24
) were also calculated. 
All AUC values were calculated by applying the log-trape-
zoidal method. The apparent volume of distribution (V
z
/F) 
of torasemide and furosemide was calculated as V
z
/F=D/ 
(k
e
 *AUC
0–∞), where D is dose and F is bioavailability. Total 
oral clearance (Cl/F) was calculated as D/AUC
0–t
.
The cumulative amount of torasemide and furosemide 
excreted up to 24 hours (A
e24
) was calculated as the sum of 
the amount of drug excreted unchanged in each time interval 
up to 24 hours. The cumulative amount excreted up to infinity 
(A
e∞) was calculated as the AUC extrapolated to infinity.
The diuretic effect was measured as the volume of urine 
obtained during the various urine collection intervals and 
the volume of urine collected at 24 hours and diuresis rate, 
expressed as milliliters per minute or milliliters per hour.
Calculation of all pharmacokinetic parameters (plasma 
and urine) and electrolytes in the urine were based on a 
noncompartmental model using WinNonlin version 2.1 
(Pharsight Corporation, St Louis, MO, USA).
samples analyses
Bioanalytical assays were previously validated (unpublished 
data, 2011) and performed at the Dr F Echevarne Analytical 
Laboratory, (Barcelona, Spain) in accordance with Good 
Laboratory Practices Guidelines.
Plasma and urine concentrations of torasemide and 
furosemide were determined through the method of liquid 
chromatography coupled to tandem mass spectrometry 
(triple quadrupole). Samples containing torasemide and 
furosemide were thawed at room temperature and centrifuged 
at 3,000 rpm for 5 minutes. The calibration line ranged from 
1 ng/mL to 2,500 ng/mL (plasma samples) and from 1 ng/mL 
to 1,000 ng/mL (urine samples). The coefficient of varia-
tion (CV) at concentrations of 3 ng/mL, 1,000 ng/mL, and 
2,000 ng/mL of torasemide in plasma samples was 10.3%, 
9.9%, and 5.9%, respectively. The CV at concentrations of 
3 ng/mL, 500 ng/mL, and 800 ng/mL of torasemide in urine 
samples was 10.5%, 5.5%, and 4.8%, respectively. Regard-
ing furosemide, the calibration line ranged from 25 ng/mL 
to 2,000 ng/mL (plasma samples) and from 25 ng/mL to 
5,000 ng/mL (urine samples). The CV at concentrations of 
75 ng/mL, 800 ng/mL, and 1,600 ng/mL of furosemide in 
plasma samples was 4.4%, 4.8%, and 4.5%, respectively. 
The CV at concentrations of 75 ng/mL, 2,500 ng/mL, and 
4,000 ng/mL of furosemide in urine samples was 5.8%, 4.0%, 
and 3.4%, respectively.
The limit of quantification was 1 ng/mL for torasemide 
and 25 ng/mL for torasemide. All samples were analyzed 
within the frozen stability period. Chromatography separa-
tion was performed using an analytical column Phenomenex 
LUNA C18 (150×4.6 mm) 5 μm in all cases.
For pharmacodynamics, urine sodium, chloride, and 
potassium were measured by indirect potentiometry using 
ion-selective electrodes (Integra 800; Roche Diagnostics 
SL, Barcelona, Spain) at the Biochemistry laboratory of 
the Hospital de la Santa Creu i Sant Pau. Measurements are 
expressed in millimoles per liter.
safety and tolerability
Safety was assessed measuring blood pressure, heart 
rate, respiratory rate, body temperature at baseline and 
0.5 hour, 1 hour, 2.5 hours, 3.5 hours, 4.5 hours, 7 hours, 
10 hours, 18 hours, and 24 hours after study drug administra-
tion. Laboratory analyses were performed before and after 
each period. Adverse events were recorded throughout the 
study period. An ECG was performed at the inclusion and 
24 hours after drug administration in each period.
statistical methods
The sample size was calculated assuming a 60% intrain-
dividual variability of furosemide and considering data 
described by Vargo et al6 for torasemide, on the basis of an 
estimated difference of 20% in natriuretic efficiency between 
both drugs. As a result, 30 patients with a maximum sex 
imbalance of 60%:40% in either direction were planned for 
study inclusion.
An exploratory analysis of the plasma parameters was 
carried out by plotting the mean of the raw data for the three 
treatments obtained in the study. The population for the 
primary analysis was per protocol population (defined as all 
randomized patients who received study medication for at 
least the two first periods and with no major deviations).
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The difference in natriuretic efficiency between 
torasemide-PR and furosemide-IR was formally tested by 
means of a one-way analysis of variance (ANOVA) (formula-
tion) of repeated measures followed by a post hoc analysis to 
assess the differences between both formulations. Secondary 
pharmacokinetic plasma parameters (C
max
, AUC
0–t
, AUC
0–∞, 
t
1/2
, Vd/F, Cl/F, t
max
, and mean residence time (MRT), phar-
macokinetic urine parameters (ER
max
, A
e24
, and A
e∞), and 
urine pharmacodynamic variables (diuresis effect, ER
Na
, ER
K
, 
and ER
Cl
) were analyzed for descriptive and comparative 
purposes. For comparisons between the three formulations 
(torasemide-PR, furosemide-PR, and torasemide-IR) a one-
way ANOVA (formulation) of repeated measures followed 
by a post hoc analysis was applied to assess the differences by 
pairs. The test was two sided at the 5% significance level.
All statistical analyses were performed using SPSS/WIN 
18 (SPSS Inc., Chicago, IL, USA).
Results
study subjects
Due to low recruitment rates, only 10 out of the 30 planned 
patients were included in the study (eight males and two 
females) and nine patients completed the study. One patient 
was excluded before taking any study drug on D-1 and, 
therefore, all pharmacokinetic, pharmacodynamic, and safety 
analyses were performed on nine patients.
The demographic and baseline characteristics of included 
patients are shown in Table 2. Treatments were angiotensin 
converting enzyme inhibitors or angiotensin receptor 
antagonists (seven patients were treated with enalapril, one 
with ramipril, and one with valsartan), beta blockers (two 
patients received carvedilol and seven received bisoprolol), 
and diuretics (eight patients received diuretics). Three 
patients were taking mineral corticoid receptor antagonists 
that were transiently removed and restarted at the end of the 
study. Patients maintained an appropriate sodium balance, 
assessed by a stable weight (P=0.152), and no changes in 
sodium excretion (P=0.141) were observed between D-4 
and D-1. A post hoc comparison of baseline (within 12 hours 
just before drugs administration) electrolytes (Na, K, and Cl) 
and Cr showed no differences between groups (Na: P=0.477; 
K: P=0.223; Cl: P=0.515; Cr: P=0.631).
Natriuresis efficiency
The timecourse of each drug excretion rate (Figure 2) had an 
important influence on the natriuretic efficiency. The sodium 
excretion rate (ER
Na
) was found to be similar between each 
drug administered (Table 3). Mean natriuretic efficiency 
obtained over the 24 hours collection interval was signifi-
cantly higher for both torasemide formulations compared 
to furosemide (P,0.0001). No significant differences were 
found between PR and IR torasemide formulations (P=0.855; 
Table 3).
The timecourse of natriuresis efficiency (Figure 3) shows 
that torasemide-IR induced the highest natriuresis efficiency 
during the first time interval (basal, 0.5 hour). Afterward, 
natriuresis efficiency was higher with torasemide-PR. 
Furosemide showed the lowest natriuretic efficiency from 
0.25 hour until the end of the collection interval.
Plasma pharmacokinetics
Measured plasma concentrations ranged from 3.58 ng/mL 
to 1,781.53 ng/mL for torasemide-IR, from 27.55 ng/mL to 
1,903.42 ng/mL for furosemide-IR, and from 3.20 ng/mL to 
975.52 ng/mL for torasemide-PR. Plasma concentration–time 
curves of torasemide-IR, furosemide-IR, and torasemide-PR 
are shown in Figure 4.
The descriptive statistics of the pharmacokinetic plasma 
parameters are summarized in Table 4. Torasemide-IR 
was more rapidly absorbed than torasemide-PR and 
Table 2 Demographic and baseline characteristics of chronic 
heart failure patients (n=10)
Parameter Mean (SD) Median (min–max)
age (years) 63.20 (12.44) 65 (47–81)
Body weight (kg) 80.34 (13.16) 79 (66–105)
height (cm) 169.50 (8.63) 168.5 (153–186)
Body mass index  
(weight [kg]/height [m2])
27.60 (3.69) 27.95 (20.8–34.4)
ejection fraction 39 (13) 34 (26–65)
Abbreviations: max, maximum; min, minimum; sD, standard deviation.
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Figure 2 Mean urine excretion rate (μg/h) vs middle point (hours) of 10 mg 
torasemide-ir (Δ), 10 mg torasemide-Pr (), and 40 mg furosemide-ir (•).
Notes: Data points are presented as the mean of the time-course of each drug 
excretion rate in urine. The first collected interval starts at 0 hours, after the 
ingestion of the drugs.
Abbreviations: ir, immediate release; Pr, prolonged release.
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Table 3 ermax, erna, and natriuresis efficiency after oral torasemide-IR 10 mg, furosemide-IR 40 mg, and torasemide-PR 10 mg (N=9)
Parameter Torasemide-IR Furosemide-IR Torasemide-PR
ermax (μg/h)*
arithmetic mean (sD) 555.24 (205.0) 3,186.84 (1,410.1) 404.38 (79.5)
Median (min–max) 533.52 (324.3–913.2) 2,798.85 (1,091.6–5,316.5) 416.99 (262.3–503.0)
erna (mmol/h)
arithmetic mean (sD) 82.61 (28.6) 81.63 (38.5) 83.19 (37.1)
Median (min–max) 87.01 (40.0–119.0) 78.02 (36.5–143.8) 65.33 (41.5–138.5)
Natriuresis efficiency* (mmol/μg)
arithmetic mean (sD) 0.091 (0.024) 0.015 (0.007) 0.096 (0.03)
Median (min–max) 0.08 (0.06–0.13) 0.017 (0.01–0.03) 0.1 (0.06–0.13)
Note: *P,0.0001 (both torasemide formulations vs furosemide). Data are the mean (sD) and median (min-max) of the pharmacodynamic parameters obtained for the three 
formulations.
Abbreviations: ermax, drug’s excretion rate; erna, sodium excretion rate; h, hour; ir, immediate release; max, maximum; min, minimum; Pr, prolonged release; sD, standard 
deviation.
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Figure 3 Mean natriuresis efficiency (mmol/μg) following oral administration of 
10 mg torasemide-ir (Δ), 10 mg torasemide-Pr (), and 40 mg furosemide-ir (•) 
plotted against the midpoint (hours) of the entire collection interval.
Notes: Data points are time-course (expressed as midpoint of the entire collected 
interval) of the mean natriuresis efficiency, calculated as the ratio between drug-
induced natriuresis and drug recovered in urine over 24 hours.
Abbreviations: ir, immediate release; Pr, prolonged release.
furosemide-IR; achieving C
max
 1±0.4 hours after intake, 
whereas furosemide t
max
 was 1.6±0.8 hours and torasemide-PR 
t
max
 was 1.8±0.4 hours. The lowest C
max
 (807.1±138.8 ng/mL) 
was observed for torasemide-PR versus furosemide-IR 
and torasemide-IR (1 ,039.9±415.4  ng/mL and 
1,252.5±299.7 ng/mL, respectively).
Urine pharmacokinetics/
pharmacodynamics
Table 5 shows the summarized urine pharmacokinetics. The 
cumulative amount of torasemide, both IR and PR formula-
tions, was lower than that of furosemide-IR. Potassium and 
chlorine excretion rates were numerically slightly higher 
and lower for furosemide, respectively, compared to either 
formulation of torasemide.
Diuretic effect
The 0–24 hours diuretic effect for all evaluated drugs 
was similar. The total volume of urine collected after 
torasemide-PR was 2,335.1 mL at a diuresis rate of 
97.3 mL/h. After torasemide-IR, the total volume of urine 
collected was 2,422.7 mL at a diuresis rate of 100.9 mL/h 
and after furosemide-IR, the total volume of urine collected 
was 2,478.7 mL at a diuresis rate of 103.3 mL/h.
The urine volume–time curves (Figure 5) show that in the 
interval from administration to +1.75 hours, torasemide-PR 
treatment resulted in a smaller quantity of excreted urine 
compared to both IR drugs. By contrast, in the interval 
from +3.5 hours to +10 hours torasemide-PR induced a 
larger volume of urine excretion compared to the other two 
IR formulations. In short, furosemide-IR and torasemide-IR 
induced urine excretion sooner than torasemide-PR.
subjective urinary urgency
The higher mictional urgency (41.78 mm), based on a VAS, 
was reported with furosemide-IR at the 1–1.5 hours interval 
after administration. Highest mictional urgency reported 
with torasemide-IR and torasemide-PR was 33.1 mm at the 
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Figure 4 Mean plasma concentration–time curves (ng/ml–hours) of 10 mg 
torasemide-ir (Δ), 10 mg torasemide-Pr (), and 40 mg furosemide-ir (•).
Abbreviations: ir, immediate release; Pr, prolonged release; cp, plasma 
concentrations.
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Table 4 summary of PK parameters in plasma (n=9)
Parameter Torasemide-IR Furosemide-IR Torasemide-PR
Cmax (ng/ml)
arithmetic mean (sD) 1,252.5 (299.7) 1,039.9 (415.4) 807.1 (138.8)
Median (min–max) 1,257.9 (846.1–1781.5) 922.6 (508.3–1903.4) 826.7 (558.8–975.5)
P-value
Torasemide-ir – 0.262 0.002
Furosemide-ir – – 0.313
Torasemide-Pr – – –
tmax (h)
arithmetic mean (sD) 1.0 (0.4) 1.6 (0.8) 1.8 (0.4)
Median (min–max) 1.0 (0.5–1.7) 1.5 (1–3.5) 1.7 (1.2–2.5)
P-value
Torasemide-ir – 0.028 0.012
Furosemide-ir – – 0.246
Torasemide-Pr – – –
aUc0–t (ng h/ml)
arithmetic mean (sD) 3,976.3 (1277.0) 3,540.9 (776.6) 4,362.1 (1386.5)
Median (min–max) 4,050.15 (2131.9–5875.0) 3,753.2 (2119.5–4528.2) 4,188.0 (2616.9–6907.7)
P-value
Torasemide-ir – 0.321 0.031
Furosemide-ir – – 0.091
Torasemide-Pr – – –
aUc0–∞ (ng h/ml)
arithmetic mean (sD) 4,096.4 (1386.8) 3,761.1 (852.4) 4,496.8 (1516.7)
Median (min–max) 4,200.3 (2154.2–6255.3) 3,896.4 (2244.6–4764.9) 4,252.5 (2648.4–7396.7)
P-value
Torasemide-ir – 0.674 0.041
Furosemide-ir – – 0.231
Torasemide-Pr – – –
Ke (l/h)
arithmetic mean (sD) 0.14 (0.02) 0.32 (0.13) 0.15 (0.02)
Median (min–max) 0.15 (0.11–0.17) 0.34 (0.14–0.52) 0.16 (0.11–0.17)
P-value
Torasemide-ir – 0.014 0.425
Furosemide-ir – – 0.021
Torasemide-Pr – – –
t1/2 (h)
arithmetic mean (sD) 4.92 (0.77) 2.65 (1.32) 4.65 (0.80)
Median (min–max) 4.60 (4.01–6.17) 2.01 (1.32–4.73) 4.39 (3.94–6.55)
P-value
Torasemide-ir – 0.004 0.499
Furosemide-ir – – 0.019
Torasemide-Pr – – –
Vd/F (l)
arithmetic mean (sD) 18.5 (4.8) 41.4 (19.0) 15.9 (3.9)
Median (min–max) 16.2 (13.8–28.8) 42.3 (19.5–77.8) 15.4 (10.1–22.3)
P-value
Torasemide-ir – 0.023 0.014
Furosemide-ir – – 0.015
Torasemide-Pr – – –
cl/F (l/h)
arithmetic mean (sD) 2.7 (0.98) 11.2 (3.1) 2.4 (0.8)
Median (min–max) 2.4 (1.6–4.6) 10.3 (8.4–17.8) 2.3 (1.3–3.8)
P-value
Torasemide-ir – ,0.0001 0.046
Furosemide-ir – – ,0.0001
Torasemide-Pr – – –
(Continued)
Drug Design, Development and Therapy 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4299
Pharmacodynamics of torasemide-Pr in with chronic heart failure
Table 4 (Continued)
Parameter Torasemide-IR Furosemide-IR Torasemide-PR
MrT (h)
arithmetic mean (sD) 4.5 (1.0) 3.8 (1.1) 5.4 (0.9)
Median (min–max) 4.5 (3.2–6.3) 3.6 (2.5–5.9) 5.5 (4.2–6.8)
P-value
Torasemide-ir – 0.243 ,0.0001
Furosemide-ir – – 0.008
Torasemide-Pr – – –
Notes: Data are mean (SD) and median (min-max) for every pharmacokinetic parameter. Significance for parameters was tested by means of a one-way analysis of variance 
(ANOVA) followed by a post hoc analysis to assess differences by pairs. Bold values indicate statistical significance. 
Abbreviations: aUc, area under the curve; Cmax, maximum plasma concentration; cl/F, clearance; h, hours; Ke, elimination rate constant; max, maximum; min, minimum; 
MrT, mean residence time; PK, pharmacokinetic; ir, immediate-release; Pr, prolonged release; tmax, time to reach Cmax; t1/2, elimination half-life; Vd/F, volume of distribution; 
sD, standard deviation.
Table 5 PK/PD urinary parameters (n=9)
Parameter Torasemide-IR Furosemide-IR Torasemide-PR
Ae24 (μg)
arithmetic mean (sD) 1,805.14 (502.8) 13,586.26 (4,061.2) 2,020.50 (757.4)
Median (min–max) 1,700.29 (1,145.7–2,961.4) 15,346.48 (5,620.4–18,586.0) 2,146.61 (1,052.6–3,688.1)
P-value
Torasemide-ir – ,0.0001 0.214
Furosemide-ir – – ,0.0001
Torasemide-Pr – – –
Ae∞ (μg)
arithmetic mean (sD) 1,869.75 (512.8) 13,953.82 (3,887.4) 2,109.94 (765.6)
Median (min–max) 1,831.38 (1,160.2–3,024.3) 15,672.18 (6,347.8–18,757.1) 2,223.9 (1,085.02–3,768.1)
P-value
Torasemide-ir – ,0.0001 0.155
Furosemide-ir – – ,0.0001
Torasemide-Pr – – –
erK (mmol/h)
arithmetic mean (sD) 29.75 (9.6) 33.51 (8.6) 29.08 (10.1)
Median (min–max) 31.98 (16.7–45.5) 32.21 (22.81–44.40) 26.45 (18.2–50.8)
P-value
Torasemide-ir – 0.588 0.996
Furosemide-ir – – 0.435
Torasemide-Pr – – –
ercl (mmol/h)
arithmetic mean (sD) 98.69 (30.0) 93.46 (40.0) 95.06 (38.4)
Median (min–max) 110.96 (53.0–131.0) 101.55 (36.4–147.0) 74.46 (54.3–152.2)
P-value
Torasemide-ir – 0.678 0.939
Furosemide-ir – – 0.994
Torasemide-Pr – – –
Notes: Data are mean (SD) and median (min-max) for every pharmacokinetic and pharmacodynamic parameter. Significance for parameters was tested by means of a one-
way analysis of variance (ANOVA) followed by a post hoc analysis to assess differences by pairs. Bold values indicate statistical significance.
Abbreviations: Ae24, cumulative amount of drug excreted up to 24 hours; Ae∞, cumulative amount of drug excreted up to infinity; ERK, potassium excretion rate; ercl, chlorine 
excretion rate; h, hour; max, maximum; min, minimum; PK/PD, pharmacokinetic/pharmacodynamic; ir, immediate-release; Pr, prolonged release; sD, standard deviation.
interval 1.5–2 hours postdose and 34.1 mm at the interval 
3–4 hours postdose, respectively.
safety and tolerability
No serious adverse events were recorded during the study. 
Three patients reported a total of nine adverse events, seven 
of which were considered to be related to study medication 
and were transient. Among these, two adverse events were 
evaluated as mild (abdominal distension, asthenia) and 
five were moderate (three reports of increased urea in one 
patient, two reports of increased triglycerides in another 
one patient). Other deviations in laboratory findings were 
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Figure 5 Mean urine volume excreted (ml) after 10 mg torasemide-ir (Δ), 10 mg 
torasemide-Pr (), and 40 mg furosemide-ir (•) plotted against the midpoint (hours) 
of the entire collection interval.
Notes: The entire collection interval comprise 10 different intervals after the drug 
ingestion from 0 h to 24 h.
Abbreviations: ir, immediate release; Pr, prolonged release.
not considered clinically relevant. There were no clinically 
relevant deviations on cardiologic parameters, that is, blood 
pressure, heart rate, and ECG. There were no withdrawals 
related to adverse events.
Discussion
Loop diuretics inhibit the sodium–potassium–chloride 
transporter in the thick ascending limb of the loop of 
Henle, resulting in a decreased reabsorption of sodium, 
chloride, and water.16 Furosemide was the first loop diuretic 
approved by the Food and Drug Administration in 1966, 
and torasemide is the most recently approved loop diuretic 
in 1993.16 With the exception of the actual drug, the type 
of release of a drug’s formulation has been revealed to be 
an important factor for not only pharmacokinetics but also 
pharmacodynamics.13,17,18
Regarding diuretics, a key pharmacodynamic endpoint 
is efficiency, a parameter that describes the effect of a drug 
in terms of effect per unit of concentration, and particularly 
useful for those drugs following concentration–effect rela-
tionships according to maximum effect or sigmoid maximum 
effect models.15 It is known that with identically administered 
doses of certain diuretics, such as furosemide in healthy 
volunteers19,20 or bumetanide in chronic renal insufficiency21 
and in CHF (classes II–III),22 constant inputs induce higher 
total effects than rapid inputs, meaning that sustained drug 
concentrations elicit higher effect than oscillating concentra-
tions with large differences between peaks and troughs. The 
present study was designed to compare natriuretic efficiency 
of equivalent doses of PR torasemide and IR furosemide. 
Previous results showed that a PR formulation of torasemide 
was associated with higher natriuretic efficiency than an 
IR torasemide formulation in healthy volunteers.13 Results 
from our study show that the amount of sodium excreted per 
molecule by the loop of Henle is higher with torasemide-PR 
than with furosemide-IR. Therefore, a higher natriuretic 
efficiency was reached with torasemide-PR. Similarly, 
torasemide-IR was also shown in our study population to 
enhance natriuretic efficiency compared to furosemide-IR. 
Nevertheless, no significant differences were found between 
both formulations of torasemide, which may be the result of, 
or influenced by, an insufficient sample size. The natriuresis 
efficiency results obtained in our study for furosemide-IR are 
very similar to the results obtained for furosemide by Alván 
et al.18 Alván et al investigated the bioavailability and diuretic 
effect of two oral controlled release formulations and a plain 
tablet of furosemide and they found that natriuretic efficiency 
after controlled release formulations of furosemide were 
higher than after the plain formulation. These findings are in 
agreement with our results obtained with the torasemide-PR 
formulation investigated.
The pharmacokinetic results of the present study are in 
accordance with the known kinetic characteristics of the 
three study medications. Torasemide-PR shows a typical PR 
profile, reaching a lower maximum concentration (P=0.002) 
over a longer period of time (P=0.012) and with a more 
gradual decrease in plasmatic concentrations compared to 
the IR formulation. In addition, the pharmacokinetic param-
eters of PR and IR torasemide formulations were in general 
comparable to those obtained in a previous study in healthy 
subjects.13 The time to maximum concentration was signifi-
cantly longer with the PR formulation than with the IR in 
healthy volunteers (1.5 hours vs 0.7 hours)13 and at a similar 
magnitude of difference compared to this study (1.7 hours 
vs 1.0 hours). In a previous study of patients with HF,6 a 
similar t
max
 mean (1.1 hours) was already shown with a 10 mg 
dose of torasemide-IR; these results are similar to the results 
observed in our study. Results obtained by Barbanoj et al13 
also showed that in healthy volunteers the C
max
 achieved 
with a PR torasemide formulation was 32% lower than with 
the IR formulation. In our study, despite obtaining slightly 
lower absolute concentrations, the C
max
 reached with the PR 
formulation was 36% lower than with the IR formulation. It is 
known that low cardiac output with reduced intestinal perfu-
sion and decreased intestinal motility affect drugs absorption 
and may lead to lower C
max
 and delayed t
max
 in HF patients 
compared to healthy subjects.7 Despite this, the relative dif-
ference due to formulation was maintained regardless the 
clinical condition of the patients with HF.
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Pharmacodynamics of torasemide-Pr in with chronic heart failure
Results from the present study suggest that treatment 
with torasemide is related with less urinary urgency. This is 
in agreement with the results from a clinical trial conducted 
to evaluate efficacy and quality of life in patients with HF 
NYHA II–IV who received torasemide or furosemide over 
nine months.3 Quality-of-life was defined in the trial as a com-
pound endpoint, with urinary urgency being one of its items. 
The number of mictions was also lower in the torasemide 
group compared to furosemide, and the authors concluded 
that torasemide was associated with less functional and social 
limitations in patients with CHF under treatment.3 Although 
urinary urgency was measured through a different method in 
the present study, our results show numeric differences in the 
same direction than the mentioned clinical trial.
For both formulations of torasemide, similar results were 
observed regarding diuretic effect, urine volume–time, and 
urinary urgency. Considering data from urine volume–time 
curves and times for highest VAS scoring between PR and IR 
torasemide formulations, the rate of drug release may have a 
role in improving symptoms by delaying urinary urgencies, 
which may potentially impact patients’ quality of life.3
Safety data from the present study confirm that 
torasemide-PR is a safe and well-tolerated drug, in accor-
dance with the known safety profile of this drug.3,6,13,23
One limitation of the study was the low number of 
patients enrolled, so the study could not reach the expected 
sample size, limiting the possibility to detect further differ-
ences between the studied formulations. Despite this study 
not assessing clinical endpoints, our findings suggest that 
torasemide-PR may be a preferred option for chronic stable 
HF patients, due to its better tolerability and natriuretic effi-
ciency. In this sense and due to the limited sample size, it 
would be desirable to perform additional studies to provide 
further information about clinical endpoints (eg, decompen-
sation or hospital readmissions) in chronic HF patients treated 
with PR formulations of loop diuretics.
In conclusion, the findings from this study suggest 
that torasemide-PR was more natriuretically efficient 
than furosemide-IR after a single-dose administration in 
patients with chronic HF, over the 24-hour collection period 
evaluated.
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